The Dietary Supplement Listing Act of 2026 requires manufacturers of dietary supplements sold in the United States to register their products with the Food and Drug Administration (FDA) and provide detailed information about each supplement. Manufacturers must submit product names, ingredients, dosages, labels, usage directions, warnings, allergen information, and health claims within 18 months of the bill's enactment (by approximately July 2027 for products already on the market), while new dietary supplements must be registered at the time they enter commerce. The FDA will assign each registered product a listing number and create a publicly searchable electronic database containing this information by 2028, though certain details like proprietary blend quantities, manufacturer contact information, and company locations will remain confidential. The bill authorizes approximately $7.9 million for fiscal year 2026 and $6.6 million annually through 2030 to implement the registration system and enforce compliance. The law does not grant the FDA authority to approve dietary supplements before they are marketed and maintains existing protections for trade secret information.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.